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Introduction {#ss1}
============

Rapid influenza diagnostic tests (RIDTs) detect Influenza A and B viral nucleoprotein (NP) from respiratory specimens. Specific antibodies are used to capture the NP on a membrane with test results generated in 10--15 minutes. Rapid influenza diagnostic tests have been shown to be highly specific; however, several reports have shown that RIDT analytical and clinical sensitivity varies.[^1^](#b1){ref-type="ref"}, [^2^](#b2){ref-type="ref"}, [^3^](#b3){ref-type="ref"} Additionally, the type of specimen collected, time from illness onset to collection of respiratory specimen, and prevalence of influenza activity in the population have been shown to affect RIDT results.[^4^](#b4){ref-type="ref"}

The emergence of a variant virus in 2009 highlighted the need to evaluate the reactivity of RIDTs as the NP from influenza A(H1N1)pdm09 originated from swine rather than human viruses.[^5^](#b5){ref-type="ref"} Reduced reactivity of RIDTs with influenza A(H1N1)pdm09 in comparison with seasonal influenza viruses[^6^](#b6){ref-type="ref"}, [^7^](#b7){ref-type="ref"}, [^8^](#b8){ref-type="ref"}, [^9^](#b9){ref-type="ref"}, [^10^](#b10){ref-type="ref"} is of public health concern. Rapid influenza diagnostic tests were found to be capable of detecting influenza A(H1N1)pdm09 in respiratory specimens, but many infections could be missed, especially in specimens with low viral loads.[^10^](#b10){ref-type="ref"}

Between 1990 and 2010, 27 human cases of infection with variant influenza viruses that contain one or more gene segments derived from viruses of swine origin were identified in the United States.[^11^](#b11){ref-type="ref"} These variant viruses were of different subtype \[A(H1N1)v, A(H1N2)v, and A(H3N2)v\] and genome constellations. In 2010, the increase in the number of human infections with H3N2v viruses prompted the preparation of a candidate vaccine virus, A/Minnesota/11/2010 (H3N2)v. In July 2011, the first human case of infection with a new reassortant influenza A(H3N2)v virus containing the matrix (M) gene from influenza A(H1N1)pdm09 virus was detected.[^12^](#b12){ref-type="ref"}, [^13^](#b13){ref-type="ref"} From July 2011 through August 9, 2012, a total of 166 human infections with H3N2v viruses have been reported.[^13^](#b13){ref-type="ref"}, [^14^](#b14){ref-type="ref"}

Increasing numbers of human infections with variant viruses prompted the investigation of the analytical reactivity of FDA‐cleared RIDTs with these viruses. To determine whether RIDTs can detect influenza A(H3N2)v in addition to A(H1N1)v and A(H1N2)v viruses, seven FDA‐cleared RIDTs were evaluated analytically with variant viruses as well as with circulating human influenza A(H3N2) and A(H1N1)09pdm viruses. A public health message describing updated influenza A(H3N2)v virus case counts and an abbreviated data set was published recently in the Morbidity and Mortality Weekly Report.[^14^](#b14){ref-type="ref"} This manuscript provides additional data and discussion describing reactivity and genetic comparisons with seasonal viruses and additional influenza A variant viruses.

Materials and methods {#ss2}
=====================

RIDTs {#ss3}
-----

Seven FDA‐cleared RIDTs were evaluated ([Table 1](#t1){ref-type="table-wrap"}). Four of the RIDTs were Clinical Laboratory Improvement Amendment (CLIA)‐waived. CLIA‐waived tests can be performed in point‐of‐care settings such as physician offices. Test time for all RIDTs was between 10 and 15 minutes. Two of the RIDTs required a manufacturer‐specific analyzer to determine the results of the test. BinaxNOW^®^(BinaxNOW, Scarborough, ME, USA), Directigen™ (Directigen, Sparks, MD, USA), FluAlert (FluAlert, San Antonio, TX, USA), QuickVue^®^ (QuickVue, San Diego, CA, USA), and Sofia (Sofia, San Diego, CA, USA) tests were performed according to the procedures in the kit inserts for nasal washes or aspirates. Xpect™ (Xpect, Lenexa, KS, USA) tests were performed according to their procedure for nasal washes and swab specimens transported in liquid media. For the Veritor™ (Veritor, Sparks, MD, USA), 100 microliters of diluted sample were added directly to the reagent tube. Positive and negative controls contained in each RIDT were run prior to testing the viruses in the study to verify performance of each lot, with the exception of FluAlert, which does not provide controls. Five tenfold serial dilutions in 0·85% physiological saline were prepared for each virus immediately before testing all seven RIDTs in duplicate. Only specimens that tested positive for both replicates were interpreted as positive. If the internal control in the test was invalid or the analyzer reported an invalid result, the test was repeated.

###### 

Rapid Influenza Diagnostic Tests (RIDTs) used in the study

  RIDT (Manufacturer)                                                      Abbreviated name   CLIA Complexity   Approved specimens\*                 Analyzer for interpretation
  ------------------------------------------------------------------------ ------------------ ----------------- ------------------------------------ -----------------------------
  BinaxNOW^®^ Influenza A&B (Alere)                                        BinaxNOW^®^        Waived            NP swab /Nasal wash/aspirate/swab    No
  Directigen™ EZ Flu A + B (Becton‐Dickinson)                              Directigen™ EZ     Not waived        NP wash/aspirate/swab /Throat swab   No
  SAS™ FluAlert A&B (SA Scientific)                                        FluAlert           Not waived        Nasal wash/aspirate                  No
  QuickVue^®^ Influenza A + B Test (Quidel)                                QuickVue^®^        Waived            NP swab /Nasal wash/aspirate/swab    No
  Sofia Influenza A + B (Quidel)                                           Sofia              Waived            NP aspirate/swab/wash /Nasal wash    Required
  BD Veritor™ System for Rapid Detection of Flu A + B (Becton Dickinson)   Veritor™           Waived            NP swab/nasal swab                   Required
  XPECT™ Flu A&B (Remel)                                                   Xpect™             Not waived        Nasal wash/swab /Throat swab         No

\*Approved respiratory specimens according to manufacturer's package insert. Test performance has only been demonstrated for these specimen types.

NP, nasopharyngeal; CLIA, Clinical Laboratory Improvement Amendment.

Viruses {#ss4}
-------

Influenza A viruses used in the study are listed in [Table 2](#t2){ref-type="table-wrap"}. The viruses were grown in Madin--Darby Canine Kidney cells from ATCC collection (CCL‐34) as previously described.[^15^](#b15){ref-type="ref"} The 50% tissue culture infectious dose (TCID~50~/ml) was measured to estimate the amount of infectious virus in a sample as described.[^16^](#b16){ref-type="ref"}

###### 

Lowest virus concentration (TCID~50~/ml) detected in evaluated RIDTs

  Subtype     Strain designation        TCID~50~/ml   RIDT                                                         
  ----------- ------------------------- ------------- --------- ---------- --------- --------- --------- --------- ---------
  H3N2        A/Georgia/01/2011         10^6·0^       10^2·0^   10^1·0^    10^4·0^   10^1·0^   10^1·0^   10^2·0^   10^3·0^
  H1N1pdm09   A/California/04/2009      10^6·0^       10^4·0^   10^2·0^    U         10^4·0^   10^3·0^   10^2·0^   10^3·0^
  H3N2v       A/Kansas/13/2009          10^4·5^       10^3·5^   10^−0·5^   U         U         10^2·5^   10^0·5^   10^0·5^
  H3N2v       A/Pennsylvania/14/2010    10^4·5^       10^2·5^   10^−0·5^   U         10^2·5^   10^2·5^   10^0·5^   10^1·5^
  H3N2v       A/Minnesota/11/2010       10^4·5^       U         10^1·5^    U         U         10^1·5^   10^1·5^   10^2·5^
  H3N2v       A/Indiana/08/2011         10^6·0^       10^5·0^   10^3·0^    U         U         10^4·0^   10^3·0^   10^4·0^
  H3N2v       A/Indiana/10/2011         10^4·0^       U         10^1·0^    U         U         10^2·0^   10^0·0^   10^2·0^
  H3N2v       A/West Virginia/06/2011   10^6·0^       10^4·0^   10^3·0^    U         10^4·0^   10^2·0^   10^2·0^   10^4·0^
  H3N2v       A/Iowa/07/2011            10^4·5^       10^2·5^   10^0·5^    10^3·5^   10^3·5^   10^1·5^   10^0·5^   10^1·5^
  H1N1v       A/Wisconsin/28/2011       10^6·0^       10^5·0^   10^3·0^    10^5·0^   10^5·0^   10^3·0^   10^1·0^   10^2·0^
  H1N2v       A/Michigan/09/2007        10^6·0^       10^5·0^   10^4·0^    U         U         10^4·0^   10^2·0^   10^4·0^
  H1N2v       A/Minnesota/19/2011       10^5·0^       10^4·0^   10^1·0^    U         U         10^2·0^   10^0·0^   10^3·0^

RIDT, rapid influenza diagnostic test.

TCID~50~/ml, infectious titer of stock virus; U, undetected at any concentration tested.

Phylogenetic analysis {#ss5}
---------------------

The evolutionary history of the influenza A NP gene was inferred by using the maximum likelihood method based on the data‐specific model.[^17^](#b17){ref-type="ref"} The tree with the highest log likelihood (−21797·5176) is shown. Initial tree(s) for the heuristic search were obtained automatically as follows. When the number of common sites was \<100 or less than one‐fourth of the total number of sites, the maximum parsimony method was used; otherwise, BIONJ method with MCL distance matrix was used. The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis involved 89 nucleotide sequences, and GISAID accession numbers are listed in Table S1. Codon positions included were 1st + 2nd + 3rd + Noncoding. All positions containing gaps and missing data were eliminated. There were a total of 1357 positions in the final data set. Evolutionary analyses were conducted in MEGA5.[^18^](#b18){ref-type="ref"}

Results {#ss6}
=======

[Table 2](#t2){ref-type="table-wrap"} shows the lowest virus concentration (TCID~50~/ml) detected by each RIDT for each influenza virus. All RIDTs detected the seasonal influenza A/Georgia/01/2011 (H3N2) virus, although at different infectious virus titers varying from 10^1·0^ TCID~50~/ml (Directigen™, QuickVue^®^, Sofia) to 10^4·0^ TCID~50~/ml (FluAlert). All but one of the RIDTs (FluAlert) were able to detect the A/California/04/2009 (H1N1)pdm09 virus, however, at higher virus concentrations compared with A/Georgia/01/2011 (H3N2). The lowest concentrations of A/California/04/2009 (H1N1)pdm09 detected by RIDTs that provided positive results varied from 10^2·0^ TCID~50~/ml (Directigen™, Veritor™) to 10^4·0^ TCID~50~/ml (BinaxNOW^®^, QuickVue^®^).

Four of seven RIDTs in this study (Directigen™, Sofia, Veritor™, and Xpect™) detected all influenza A(H3N2)v viruses ([Table 2](#t2){ref-type="table-wrap"}). The lowest A(H3N2)v virus concentrations detected by these four RIDTs were similar to those for A/California/04/2009 (H1N1)pdm09. BinaxNOW^®^ detected five of seven and QuickVue^®^ detected three of seven A(H3N2)v viruses. FluAlert detected only one of seven A(H3N2)v viruses.

Three influenza A(H1) variant viruses also were evaluated with the seven RIDTs: two A(H1N2)v isolates (A/Michigan/09/2007, A/Minnesota/19/2011) and one A(H1N1)v virus (A/Wisconsin/28/2011) ([Table 2](#t2){ref-type="table-wrap"}). Five of seven RIDTs (BinaxNOW^®^, Directigen™, Sofia, Veritor™, and Xpect™) detected all influenza A(H1)v viruses. FluAlert and QuickVue^®^ were unable to detect two of three influenza A(H1)v viruses in this evaluation.

As the NP of influenza viruses is the target for all evaluated RIDTs, we compared predicted amino acid sequences of the NP based on available genetic data for tested viruses ([Table 3](#t3){ref-type="table-wrap"}). This amino acid alignment revealed that the NP of A/California/04/2009 (H1N1)pdm09 and the A(H3N2)v, A(H1N2)v, and A(H1N1)v viruses differ in amino acid sequences from the NP of the seasonal A/Georgia/01/2011 (H3N2) virus by 10·3--10·7%. The pandemic A/California/04/2011 (H1N1)pdm09 virus and all variant viruses tested here are different from each other by approximately 2%. There is \<0·2% difference in the amino acid composition of the NP among influenza A(H3N2)v, A(H1N2)v, and A(H1N1)v viruses tested in this study. In addition, [Figure 1](#f1){ref-type="fig"} shows the phylogenetic analysis of influenza A NP genes from various species. [Figure 1](#f1){ref-type="fig"} further demonstrates that although the NP genes in North American swine and human seasonal influenza viruses are derived from a common ancestor related to the A(H1N1) from 1918, separate species‐specific evolutionary paths have since occurred. North American swine NP is quite divergent from the NP of seasonal human influenza A viruses but more closely genetically related to NP from influenza A(H1N1)pdm09 viruses.

###### 

Nucleoprotein amino acid difference comparisons between seasonal A(H3N2), A(H1N1)pdm09, and variant influenza A viruses

  Subtype     Amino acid distance\*   Strain designation        16    18    21    31    34    38    52    53    61    65    105   109   119   131
  ----------- ----------------------- ------------------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  H3N2                                A/Georgia/01/2011         D     D     N     K     D     R     H     E     L     K     M     V     I     S
  H1N1pdm09   0·102                   A/California/04/2009      G     E     D     R     G           Y     D     I     R           I     V     A
  H3N2v       0·104                   A/Kansas/13/2009          G     E     D     R     G     K     Y           I     R           I     V     A
  H3N2v       0·104                   A/Pennsylvania/14/2010    G     E     D     R     G     K     Y           I     R           I     V     A
  H3N2v       0·105                   A/Minnesota/11/2010       G     E     D     R     G     K     Y           I     R           I     V     A
  H3N2v       0·106                   A/Indiana/08/2011         G     E     D     R     G     K     Y           I     R           I     V     A
  H3N2v       0·104                   A/Indiana/10/2011         G     E     D     R     G     K     Y           I     R           I     V     A
  H3N2v       0·104                   A/West Virginia/06/2011   G     E     D     R     G     K     Y           I     R           I     V     A
  H3N2v       0·104                   A/Iowa/07/2011            S     E     D     R     G     K     Y           I     R           I     V     A
  H1N1v       0·106                   A/Wisconsin/28/2011       G     E     D     R     G     K     Y           I     R     I     I     V     A
  H1N2v       0·104                   A/Michigan/09/2007        G     E     D     R     S     K     Y           I     R           I     V     A
  H1N2v       0·104                   A/Minnesota/19/2011       G     E     D     R     G     K     Y           I     R           I     V     A
  Subtype     Amino acid distance\*   Strain designation        186   189   190   197   214   217   239   280   283   286   289   293   306   312
  H3N2                                A/Georgia/01/2011         I     M     V     V     K     S     V     A     P     S     Y     K     L     I
  H1N1pdm09   0·102                   A/California/04/2009      V     I     A     I     R     V     M     V     L     A     H     R           V
  H3N2v       0·104                   A/Kansas/13/2009          V     I     A     I     R     I     M     V     L     A     H     R           V
  H3N2v       0·104                   A/Pennsylvania/14/2010    V     I     A     I     R     I     M     V     L     A     H     R           V
  H3N2v       0·105                   A/Minnesota/11/2010       V     I     A     I     R     I     M     V     L     A     H     R           V
  H3N2v       0·106                   A/Indiana/08/2011         V     I     A     I     R     I     M     V     L     A     H     R     S     V
  H3N2v       0·104                   A/Indiana/10/2011         V     I     A     I     R     I     M     V     L     A     H     R           V
  H3N2v       0·104                   A/West Virginia/06/2011   V     I     A     I     R     I     M     V     L     A     H     R           V
  H3N2v       0·104                   A/Iowa/07/2011            V     I     A     I     R     I     M     V     L     A     H     R           V
  H1N1v       0·106                   A/Wisconsin/28/2011       V     I     A     I     R     I     M     V     L     A     H     R           V
  H1N2v       0·104                   A/Michigan/09/2007        V     I     A     I     R     I     M     V     L     A     H     R           V
  H1N2v       0·104                   A/Minnesota/19/2011       V     I     A     I     R     I     M     V     L     A     H     R           V
  Subtype     Amino acid distance\*   Strain Designation        313   316   343   344   350   353   371   372   373   375   377   384   400   406
  H3N2                                A/Georgia/01/2011         Y     I     L     L     T     S     M     D     N     G     S     G     R     T
  H1N1pdm09   0·102                   A/California/04/2009      V     M     V     S     K     I     V     E     T     D     N     R     K     I
  H3N2v       0·104                   A/Kansas/13/2009          F           V     S     K     I     V     E     A     D     N     R     K     I
  H3N2v       0·104                   A/Pennsylvania/14/2010    F           V     S     K     L     V     E     A     D     N     R     K     I
  H3N2v       0·105                   A/Minnesota/11/2010       F           V     S     K     L     V     E     A     D     N     R     K     I
  H3N2v       0·106                   A/Indiana/08/2011         F           V     S     K     L     V     E     A     D     N     R     K     I
  H3N2v       0·104                   A/Indiana/10/2011         F           V     S     K     L     V     E     A     D     N     R     K     I
  H3N2v       0·104                   A/West Virginia/06/2011   F           V     S     K     L     V     E     A     D     N     R     K     I
  H3N2v       0·104                   A/Iowa/07/2011            F           V     S     K     L     V     E     A     D     N     R     K     I
  H1N1v       0·106                   A/Wisconsin/28/2011       F           V     S     K     L     V     E     A     D     N     R     K     I
  H1N2v       0·104                   A/Michigan/09/2007        F           V     S     K     I     V     E     A     D     N     R     K     I
  H1N2v       0·104                   A/Minnesota/19/2011       F           V     S     K     L     V     E     A     D     N     R     K     I
  Subtype     Amino acid distance\*   Strain Designation        422   423   425   426   430   433   442   444   450   455   456   459   473   498
  H3N2                                A/Georgia/01/2011         K     S     I     M     T     T     A     I     G     E     V     R     N     N
  H1N1pdm09   0·102                   A/California/04/2009      R     A     V           S     N     T     V     S     D     L     Q           S
  H3N2v       0·104                   A/Kansas/13/2009          R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H3N2v       0·104                   A/Pennsylvania/14/2010    R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H3N2v       0·105                   A/Minnesota/11/2010       R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H3N2v       0·106                   A/Indiana/08/2011         R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H3N2v       0·104                   A/Indiana/10/2011         R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H3N2v       0·104                   A/West Virginia/06/2011   R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H3N2v       0·104                   A/Iowa/07/2011            R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H1N1v       0·106                   A/Wisconsin/28/2011       R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H1N2v       0·104                   A/Michigan/09/2007        R     A     V     L     S     N     T     V     S     D     L     Q     S     S
  H1N2v       0·104                   A/Minnesota/19/2011       R     A     V     L     S     N     T     V     S     D     L     Q     S     S

\*Compared with A/Georgia/01/2011 H3N2. Gaps in the table indicate identity to amino acids of A/Georgia/01/2011 (H3N2).

![ Phylogenetic analysis of influenza A nucleoprotein genes by maximum likelihood method. Viruses used in this study are underlined.](IRV-7-491-g001){#f1}

Discussion {#ss7}
==========

As demonstrated by this evaluation, RIDTs may or may not detect the presence of NP derived from influenza viruses that are circulating in swine. Genetic sequence analysis indicates divergence of the NP of influenza A variant viruses and the A(H1N1)pdm09 virus compared with the NP of seasonal influenza A viruses, which may account for reduced reactivity with some RIDTs. It is important to note that all RIDTs have different proprietary antibodies to capture and detect NP, making it impossible to predict which RIDTs may detect NP that evolved from viruses that are not of human origin. As indicated in the manufacturer package inserts, influenza A viruses that have undergone minor amino acid changes in the target epitope region or regions may cause the antibodies to be less sensitive or not sensitive at all. Although the NP gene sequences are almost identical among variant viruses, several variant viruses were tested in this study because influenza virus preparations can be different in terms of amount of infectious/non‐infectious virus, protein concentration, etc. This may account for differences in reactivity of different viruses with RIDTs despite having similar infectious virus titers.

This first study to assess analytical reactivity of FDA‐cleared RIDTs with influenza A variant viruses has some limitations. Only seven RIDTs were evaluated when currently there are 15 FDA‐cleared RIDTs of which six are CLIA‐waived for use in point‐of‐care settings.[^4^](#b4){ref-type="ref"} Cell culture virus isolates were used for this study. Limited volumes prevented a comparison of all seven RIDTs with clinical specimens. As in most analytical evaluations, influenza viruses in this study were characterized by their infectious virus titer but not by the NP concentration. Infectious virus titer can vary among preparations of the same virus, and the titers were not normalized for the purposes of this evaluation. A side‐by‐side performance evaluation of all cleared assays with multiple influenza virus preparations, dilutions, and replicates would provide a direct analytical comparison of all FDA‐cleared RIDTs.

This study was conducted to provide public health guidance for the use of RIDTs when a novel influenza virus infection is suspected. It is important for clinicians to minimize the occurrence of false RIDT results by strictly following the manufacturer's instructions, collecting specimens soon after onset of influenza‐like illness symptoms (ideally within the first 72 hours), and confirming RIDT results by sending a specimen to a public health laboratory.[^4^](#b4){ref-type="ref"} Qualified U.S. public health laboratories and global National Influenza Centers may utilize the CDC Flu rRT‐PCR Panel and a real‐time RT‐PCR assay, which allows for the preliminary identification of influenza variant viruses possessing the swine NP gene.[^13^](#b13){ref-type="ref"} This evaluation reinforces the fact that a negative RIDT result should not be considered as conclusive evidence of a lack of infection with influenza virus and emphasizes that this may particularly be the case for influenza A(H3N2)v viruses.

Supporting information
======================

**Table S1.** GISAD accession numbers for sequences in phylogenetic tree.
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Click here for additional data file.
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